1. Home
  2. EXTR vs MLYS Comparison

EXTR vs MLYS Comparison

Compare EXTR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extreme Networks Inc.

EXTR

Extreme Networks Inc.

HOLD

Current Price

$15.20

Market Cap

2.0B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.40

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXTR
MLYS
Founded
1996
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
1999
2023

Fundamental Metrics

Financial Performance
Metric
EXTR
MLYS
Price
$15.20
$26.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$21.20
$48.67
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
04-29-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
37.43
EPS
0.10
N/A
Revenue
$1,140,067,000.00
N/A
Revenue This Year
$13.15
N/A
Revenue Next Year
$7.52
N/A
P/E Ratio
$150.85
N/A
Revenue Growth
2.05
N/A
52 Week Low
$10.11
$10.44
52 Week High
$22.89
$47.65

Technical Indicators

Market Signals
Indicator
EXTR
MLYS
Relative Strength Index (RSI) 56.51 51.05
Support Level $13.97 $22.42
Resistance Level $15.80 $31.09
Average True Range (ATR) 0.42 1.62
MACD 0.05 0.38
Stochastic Oscillator 66.42 59.63

Price Performance

Historical Comparison
EXTR
MLYS

About EXTR Extreme Networks Inc.

Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: